This discusses the Structure-Conduct-Performance (SCP) of two multinational pharmaceutical companies, Abbott Laboratories and Baxter Corporation, in three markets with radical different health care systems, the U.S., Canadian, and Brazilian markets.
Research Paper # 52262 |
16,625 words (
approx. 66.5 pages ) |
66 sources |
APA | 2004
|
$ 181.95
More information
|
New! Look inside the paper
|
Add to cart
Abstract
This paper evaluates a capitalistic market (the U.S.), a socialist/capitalistic market (Canada), and a developing market (Brazil), which can be broadly classified based on political, social, and cultural issues, to conceptually and practically understand the markets and the competition. The author points out that the generic pharmaceutical industry is flourishing in Canada; it accounts for approximately 15% of the sales of drugs in the country. The paper relates that, in Brazil, the major pharmaceutical industries are leveraging strongly on the government to change its laws and regulations in order to support better sales and distribution of the drug. Charts.
Table of Contents
Introduction
Background of the Study
Statement of the Problem
Purpose of the Study
Objectives of the Study
Limitations of Study
Definition of Terms
Literature Survey
Analysis of Factors Affecting the Pharmaceutical Company
Mergers, Acquisitions and Diversification in the Pharmaceutical Industry
History of Abbott Laboratories
The SWOT Analysis for Abbott Laboratories
Strengths of Abbott Laboratories
Weaknesses of Abbott Laboratories
Opportunity for Abbott Laboratories
Threats faced by Abbott Laboratories
History of Baxter Corporation
SWOT Analysis of Baxter Inc.
Strengths of Baxter
Weaknesses of Baxter
Opportunities Ahead for Baxter Inc.
Threats Facing Baxter
The U.S. Pharmaceutical and Healthcare Market
The Canadian Pharmaceutical and Healthcare Market
The Brazilian Pharmaceutical and Healthcare Market
Porter's Five-Force Framework for Analyzing the Pharmaceutical and Healthcare Industry
Internal Rivalry in the Global and U.S. Pharmaceutical/Healthcare Industry
Barriers to Entry
Substitutes and Complements
Buyer Power in the Different Markets of the U.S., Canada and Brazil
Bargaining Power of Suppliers
Marketing Theories
The Structure-Conduct-Performance Model for the Pharmaceutical Industry
Strategy and Nature of the Company?s Business Level Strategy
External Factors Affecting the Pharmaceutical Industry
P.E.S.T.L.E. Analysis of the Pharmaceutical Industry in all Markets
Political Analysis
Economic Analysis
Social Analysis
Technology Analysis
Legal Environment
Environmental Analysis
Conclusion
From the Paper
"Social science, economic, corporate and business strategy, public and government policies all are considered to play a significant role in the success or failure of an organization at any location around the world. In the modern marketplace, no fixed or definitive strategy can be assumed to be most effective. What may be appropriate for one company in the same industry may not exactly work for another company. Contemporary management theories place great emphasis on these variables; consequently, marketing strategies also use many of these theories to understand and evaluate the market for the product and services of the organization."
Tags:culture, generic, socialist, developing, private
A case study analysis of Abbott Laboratories' position in the pharmaceutical industry, and the extent of it's global operations.
Case Study # 108896 |
2,404 words (
approx. 9.6 pages ) |
7 sources |
APA | 2008
|
$ 44.95
More information
|
Add to cart
Abstract
This paper provides an overview of Abbott Laboratories, a research-based, global pharmaceutical company that discovers, develops, manufactures and markets leading prescription medicines as well as many of the world's best known consumer healthcare products. The paper discusses the company's position in the industry, and the extent of it's global operations. It also analyzes the company's stock, with a risk and return and valuation analysis.
Table of Contents:
Introduction
Background of Abbott Laboratories & Operations
Competition Affecting Abbott's Stock Value
Risk & Return Analysis on Abbott Laboratories Stock
Summary of Financial Data
Du Pont Analysis of Abbott Laboratories
Valuation & CAPM Analysis
Summary of Analysis
Conclusion
From the Paper
"Abbott's business practices and goals have set the pace for the company's extraordinary portfolio management practices, security of the day to day management of resources, research, and development. Abbott has successfully overcome the uncertainty in drug development and competitive pressures. Abbott's business practices continue to make Abbott a unique company and has assisted the company to maintain its' global stance in the world of pharmaceutical companies.
"Everything done at Abbott Laboratories is a reflection of the company's mission, a commitment to serving the total health-care continuum. Abbott's stock analysis concludes with the fact that competitive pressures call for an unprecedented in-depth analysis monitoring of the company stock's general risk exposure."
Tags:performance, resources, research, development
A financial ratio analysis for Abbott Laboratories.
Analytical Essay # 105730 |
1,780 words (
approx. 7.1 pages ) |
4 sources |
MLA | 2008
|
$ 34.95
More information
|
New! Look inside the paper
|
Add to cart
Abstract
This paper examines the 2006 financial status of Abbott Laboratories based on an analysis of their liquidity, solvency, profitability and asset management ratios. These financial ratios show that Abbot has solid financial policies, despite a significant increase in short-term borrowings in 2006. The paper indicates that some of the ratios show that company profitability or asset utilization has decreased at Abbott from 2004 to 2006; however, this is most likely a short-term effect of the company's strategic reorganization to target its core business sectors and of the purchases and acquisitions that have not yet had the time to show their profitability. The paper includes formulas and chart.
Table of Contents:
Introduction
Liquidity Ratios
Solvency Ratios
Profitability Ratios
Asset Management Ratios
Conclusions
From the Paper
"In our opinion, it is not something to be concerned about, since the current ratio figure in 2006 is still around the value of 1, showing that the company currently has no difficulties in covering its short-term liabilities. Nevertheless, this is something that needs to be kept under observation in the subsequent period of time, so as not to become uncontrolled. The company's policies of reducing debts show that this is a priority under observation for the company's management."
Tags:liabilities, assets, short-term, long-term, strategies
This paper is an extensive examination of the performance of Abbott Laboratories.
Case Study # 72425 |
3,375 words (
approx. 13.5 pages ) |
10 sources |
APA | 2004
|
$ 57.95
More information
|
Add to cart
Abstract
This paper presents the background of the company. The author points out the internal and external environments of Abbott Laboratories. The paper relates its strategies,organizational structure and past performance and predicts future performance..
From the Paper
" A strategic audit was performed on Abbott Laboratories. Background information is presented on the company before the findings of the analyses are presented. The analyses included in the strategic audit of the company over the company's external environment, the company's internal environment, the strategies pursued by the company, the company'organizational structure and control systems, the company's past performance and predictions of the company's future performance. Abbott Laboratories began as a home-based business ..."
Tags:Internal, analysis, External, analysis, Strategy, analysis
A Abbot Laboratories case analysis including: company description; innovative strategies in the pharmaceutical industry; management; innovative capabilities and recommendations.
Essay # 19172 |
1,350 words (
approx. 5.4 pages ) |
5 sources |
1992
|
$ 27.95
More information
|
Add to cart
From the Paper
"Abbott Laboratories
Abbott Laboratories of Chicago is one of America's major pharmaceutical companies, but it also has other products, including nutritionals and diagnostic equipment. In fact, more than half of the company's revenues come from these other products in markets where Abbott has the dominant share. Abbott also supplies such goods as intravenous fluids to hospitals and blood banks, along with pumps, screening tests, anesthetics, and critical care equipment. The company has shown innovative capabilities in terms of the development of new drugs for various purposes and has spent a good deal on research and development to create the next generation of such products. The key competition for this company includes other pharmaceutical giants such as Johnson & Johnson..."
An examination of the history and financial situation of the firm known for its pharmaceuticals, hospital products and nutritional products.
Essay # 24243 |
1,125 words (
approx. 4.5 pages ) |
4 sources |
2002
|
$ 23.95
More information
|
Add to cart
Abstract
Examines history and financial situation of the firm known for its pharmaceuticals, hospital products and nutritional products. Founding of firm. Aggressive marketing techniques. Growth of company by acquisition. Services, products, competitors. Financial analysis: income statement. Balance sheet. Ratio Analysis. Financial situation and profits. Future outlook, including restructuring. Foreign revenues.
From the Paper
"History of Firm
Abbott Laboratories, based in Abbott Park, Illinois-based company is best-known for its range of nutritional products including Similac (infant formula) and Ensure. However, the lion's share of corporate sales come from the sales of pharmaceuticals and hospital products. The company ranks 144th in the Fortune 500 and is in the S&P 500. The firm was founded in 1888 by Dr. Wallace Abbott, who began marketing and making his patented "dosimetric granule" (a formulation that allowed for uniform measurements of drugs).
In the early days, the American Medical Association thought of him as a charlatan because of his aggressive marketing techniques, although many physicians and pharmacists used his granules, since they allowed for standardization. With World War I, the Abbott team of..."
This paper discusses corporate communications in the pharmaceutical industry, especially the published annual reports of Pfizer, Abbott Laboratories, Abiomed, and World Heart Corporation.
Research Paper # 48904 |
7,510 words (
approx. 30 pages ) |
31 sources |
APA | 2004
|
$ 99.95
More information
|
New! Look inside the paper
|
Add to cart
Abstract
This paper explains that corporate communications is a method of communication in which the company is discussed without trying to promote any specific product. The author points out that corporate communications has become even more complex than it was earlier because of the development of the electronic media. The paper states that the Annual Report is a compulsory document published by every company, which is one of the primary tools in the building of the image of a company to the stock market.
Table of Contents
Introduction
Corporate Communications
The Internet
E-mail
Feedback Functions of the Internet
The Case of VNU
The Annual Report
The Annual Report of Pfizer
The Annual Report of Abbott Laboratories
The Annual Report of Abiomed
The Annual Report of World Heart Corporation
Discussion of the Companies' Annual Reports
From the Paper
"Today one of the most common tools of communications is the internet, and this was developed from an information sharing system originally developed by the US Department of Defense in the early part of the 1970s, when it was known as ARPA- Net. (Herman & Swiss, 2000). This has today grown into a worldwide network and reaches almost every computer that exists, and thus has networks linking millions of people through millions of computers. Some view this system only as an information resource, and certainly it has information resources, which can be easily tapped, but it is also a very powerful communication tool with some different ways of communication between different people in different parts of the world."
Tags:message, compulsory, electronic, vnu, visuals
This paper is a research proposal to investigate the impact of Structure-Conduct-Performance (SCP) of two multi-national pharmaceutical companies, Abbott Laboratories and Baxter Corporation, in their U.S., Canadian, and Brazilian markets.
Research Proposal # 52563 |
2,365 words (
approx. 9.5 pages ) |
4 sources |
APA | 2004
|
$ 43.95
More information
|
New! Look inside the paper
|
Add to cart
Abstract
This paper delineates the objectives of the study: (1) To determine the impact of the environment in which the organization operates by using the PESTLE and SWOT (Strengths-Weaknesses-Opportunity-Threats) analysis methods;, (2) to present a brief history of the companies and to evaluate the products manufactured and sold; (3) to understand the health care market, the impact of laws and regulations and the role of national and local governments; (4) to perform a Michael Porter's five-force analysis; and (5) to investigate the role of SCP. The author relates that this thesis will be based on a literature review and secondary data collection. The paper stresses that this study will provide useful information to policy and decision makers in the industry.
Table of Contents
Introduction
Proposed Methodology
Reflections and Potential Obstacles
Conclusion
From the Paper
"Competition is very intense in the modern day organization. Companies are increasingly striving to differentiate their products and services in the market in order to gain higher profits and a greater market share. Portfolio management, product life cycle management, decision analysis and risk analysis are becoming some of the strategies that have to be used by managers and executives all over the world. For-profit organizations are investing a lot of money and human resources to help identify variables that can make their organizations competitive in their respective markets. Failure in managing any one variable can result in the overall failure of the organization."
Tags:swat, secondary, literature, pestle, porter
An overview of issues and considerations facing the biotechnology company, Charles River Laboratories.
Research Paper # 97706 |
5,010 words (
approx. 20 pages ) |
14 sources |
MLA | 2007
|
$ 75.95
More information
|
Add to cart
Abstract
This paper provides an overview of Charles River Laboratories and the biotechnology industry in which it competes. It describes current science challenges facing the company, economic and industry concerns and financial, marketing and ethical considerations. The paper then discusses relevant regulatory issues involved in the use of laboratory animals and legal and strategic planning issues for the company. Finally, the paper describes the company's current management and leadership cadre and discusses the challenges in its consulting and staffing services.
Table of Contents:
Review and Analysis
Company Overview
Science Challenges
Economic and Industry Concerns
Financial Considerations
Marketing Considerations
Ethical Considerations
Regulatory Issues
Legal Issues
Strategic Planning Issues
Management and Leadership
Challenges in Consulting and Staffing Services
Conclusion
From the Paper
"The research showed that Charles River Laboratories is a Massachusetts-based company that was founded in 1947 and competes on a global basis today. The company provides products that have been shown to contribute in significant ways to the development of new drugs, including research models and their associated services. The research also showed that the company is subject to regulatory oversight from a wide range of national and international agencies, but has managed to not only comply with these regulations but has managed to effect substantive changes to them to their advantage over the years as well. The company has enjoyed a healthy economic performance, offset in part by recent changes in its accounting practices as described further in their latest annual report, but the bottom line outlook for Charles River Laboratories remains positive because the biotechnology industry is likewise expected to grow in exponential terms in the years to come. In sum, Charles River Laboratories is well positioned to take advantage of this explosive growth in the biotechnology field, and barring any unforeseen innovations in computer modeling applications for this purpose, demand for their products will likely continue to increase for the foreseeable future."
Tags:pharmaceutical, research, pathology, pharmacokinetics